Last reviewed · How we verify
Lipoplus 20%
Lipoplus 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat orally.
Lipoplus 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to take oral or enteral nutrition. Used for Parenteral nutrition support in patients unable to receive adequate oral or enteral nutrition, Provision of essential fatty acids and energy in critically ill or post-operative patients.
At a glance
| Generic name | Lipoplus 20% |
|---|---|
| Sponsor | B. Braun Melsungen AG |
| Drug class | Lipid emulsion for parenteral nutrition |
| Modality | Small molecule |
| Therapeutic area | Nutrition support / Critical care |
| Phase | FDA-approved |
Mechanism of action
This intravenous lipid emulsion supplies long-chain triglycerides (LCTs) derived from soybean oil, providing both energy (9 kcal/g) and essential polyunsaturated fatty acids (linoleic and alpha-linolenic acid) necessary for cell membrane integrity and metabolic function. It is used as part of total parenteral nutrition (TPN) regimens to prevent essential fatty acid deficiency and support nutritional requirements in critically ill or post-operative patients.
Approved indications
- Parenteral nutrition in patients unable to maintain adequate oral/enteral intake
- Prevention of essential fatty acid deficiency in long-term parenteral nutrition
Common side effects
- Hypertriglyceridemia
- Infusion site reactions
- Allergic reactions
- Lipemia
Key clinical trials
- The HOME Study (HPN With OMEGA-3) (PHASE4)
- Crossover Study on the Effect of Omegaven in Combination With Different Lipid Emulsions in Home Parenteral Nutrition (PHASE4)
- Different Lipid Emulsions in Acute Lung Injury Patients (PHASE4)
- ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipoplus 20% CI brief — competitive landscape report
- Lipoplus 20% updates RSS · CI watch RSS
- B. Braun Melsungen AG portfolio CI